Who
Michael R. Hayden
Director
Company insider
Files Form 4 as: Director, AbCellera Biologics; Director, Ionis Pharmaceuticals; Director, 89bio; Director, Xenon Pharmaceuticals; Director, Aurinia Pharmaceuticals.
In numbers
- Trades disclosed
- 162
- Buys
- 15
- Sells
- 1
- Bought
- $8.0M
- Sold
- $2.5M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 4 Nov 2014
- Last trade
- 24 Aug 2026
- Last filed
- 24 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Aug 2026filed 24 Aug 2026 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Bought | $570K53,613 at $10.64 | filing |
| 24 Aug 2026filed 24 Aug 2026 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Bought | $570K53,613 at $10.64 | filing |
| 12 Aug 2026filed 14 Aug 2026 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Bought | $481K46,387 at $10.37 | filing |
| 12 Aug 2026filed 14 Aug 2026 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Bought | $481K46,387 at $10.37 | filing |
| 11 Aug 2026filed 13 Aug 2026 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code G | —50,000 at $0.00 | filing |
| 11 Aug 2026filed 13 Aug 2026 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code G | —50,000 at $0.00 | filing |
| 31 Jul 2026filed 31 Jul 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $258K5,000 at $51.60 | filing |
| 31 Jul 2026filed 31 Jul 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $258K5,000 at $51.60 | filing |
| 30 Jul 2026filed 31 Jul 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $801K15,000 at $53.38 | filing |
| 30 Jul 2026filed 31 Jul 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $801K15,000 at $53.38 | filing |
| 1 Jul 2026filed 6 Jul 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,369 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,301 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,369 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,301 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —111,701 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —111,701 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —27,647 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —2,933 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —22,730 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —7,000 at $0.00 | filing |
News
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 1,357 Shares of StockIONS · dailypolitical.com · 20 Oct 2026Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)IONS · finanznachrichten.de · 16 Oct 2026AbCellera Biologics (NASDAQ:ABCL) Research Coverage Started at UBS GroupABCL · themarketsdaily.com · 15 Oct 2026Head to Head Review: Surrozen (NASDAQ:SRZN) vs. AbCellera Biologics (NASDAQ:ABCL)ABCL · tickerreport.com · 14 Oct 2026Ionis Pharmaceuticals (NASDAQ:IONS) & Upstream Bio (NASDAQ:UPB) Head to Head ReviewIONS · dailypolitical.com · 13 Oct 2026Contrasting Sarepta Therapeutics (NASDAQ:SRPT) & AbCellera Biologics (NASDAQ:ABCL)ABCL · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Michael R. Hayden; 6 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.